303 related articles for article (PubMed ID: 37922034)
21. Therapeutic applications of bioactive sphingolipids in hematological malignancies.
Ekiz HA; Baran Y
Int J Cancer; 2010 Oct; 127(7):1497-506. PubMed ID: 20503271
[TBL] [Abstract][Full Text] [Related]
22. Neutrophil elastase correlates with increased sphingolipid content in cystic fibrosis sputum.
Karandashova S; Kummarapurugu A; Zheng S; Kang L; Sun S; Rubin BK; Voynow JA
Pediatr Pulmonol; 2018 Jul; 53(7):872-880. PubMed ID: 29624923
[TBL] [Abstract][Full Text] [Related]
23. Dietary and Endogenous Sphingolipid Metabolism in Chronic Inflammation.
Norris GH; Blesso CN
Nutrients; 2017 Oct; 9(11):. PubMed ID: 29143791
[TBL] [Abstract][Full Text] [Related]
24. Effects of sphingolipid metabolism disorders on endothelial cells.
Lai Y; Tian Y; You X; Du J; Huang J
Lipids Health Dis; 2022 Oct; 21(1):101. PubMed ID: 36229882
[TBL] [Abstract][Full Text] [Related]
25. Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling.
Hamai H; Keyserman F; Quittell LM; Worgall TS
J Lipid Res; 2009 Jun; 50(6):1101-8. PubMed ID: 19144995
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and biological functions of two phosphorylated sphingolipids, sphingosine 1-phosphate and ceramide 1-phosphate.
Kihara A; Mitsutake S; Mizutani Y; Igarashi Y
Prog Lipid Res; 2007 Mar; 46(2):126-44. PubMed ID: 17449104
[TBL] [Abstract][Full Text] [Related]
27. Sphingolipids as targets for inhalation treatment of cystic fibrosis.
Becker KA; Riethmüller J; Seitz AP; Gardner A; Boudreau R; Kamler M; Kleuser B; Schuchman E; Caldwell CC; Edwards MJ; Grassmé H; Brodlie M; Gulbins E
Adv Drug Deliv Rev; 2018 Aug; 133():66-75. PubMed ID: 29698625
[TBL] [Abstract][Full Text] [Related]
28. An overview of sphingolipid metabolism: from synthesis to breakdown.
Gault CR; Obeid LM; Hannun YA
Adv Exp Med Biol; 2010; 688():1-23. PubMed ID: 20919643
[TBL] [Abstract][Full Text] [Related]
29. Sphingolipid metabolism, oxidant signaling, and contractile function of skeletal muscle.
Nikolova-Karakashian MN; Reid MB
Antioxid Redox Signal; 2011 Nov; 15(9):2501-17. PubMed ID: 21453197
[TBL] [Abstract][Full Text] [Related]
30. Sphingolipid Metabolism in Tumor Cells.
Pokrovsky VS; Ivanova-Radkevich VI; Kuznetsova OM
Biochemistry (Mosc); 2023 Jul; 88(7):847-866. PubMed ID: 37751859
[TBL] [Abstract][Full Text] [Related]
31. Sphingolipids and inflammatory diseases of the skin.
Kleuser B; Japtok L
Handb Exp Pharmacol; 2013; (216):355-72. PubMed ID: 23563666
[TBL] [Abstract][Full Text] [Related]
32. The role of sphingolipids in respiratory disease.
Yang Y; Uhlig S
Ther Adv Respir Dis; 2011 Oct; 5(5):325-44. PubMed ID: 21900155
[TBL] [Abstract][Full Text] [Related]
33. Nuclear lipid mediators: Role of nuclear sphingolipids and sphingosine-1-phosphate signaling in epigenetic regulation of inflammation and gene expression.
Fu P; Ebenezer DL; Ha AW; Suryadevara V; Harijith A; Natarajan V
J Cell Biochem; 2018 Aug; 119(8):6337-6353. PubMed ID: 29377310
[TBL] [Abstract][Full Text] [Related]
34. The role of sphingolipids in endothelial barrier function.
Jernigan PL; Makley AT; Hoehn RS; Edwards MJ; Pritts TA
Biol Chem; 2015 Jun; 396(6-7):681-91. PubMed ID: 25867999
[TBL] [Abstract][Full Text] [Related]
35. Solving the enigma: Mass spectrometry and small molecule probes to study sphingolipid function.
Millner A; Atilla-Gokcumen GE
Curr Opin Chem Biol; 2021 Dec; 65():49-56. PubMed ID: 34175552
[TBL] [Abstract][Full Text] [Related]
36. Sphingolipids Signaling in Lamellipodia Formation and Enhancement of Endothelial Barrier Function.
Fu P; Shaaya M; Harijith A; Jacobson JR; Karginov A; Natarajan V
Curr Top Membr; 2018; 82():1-31. PubMed ID: 30360778
[TBL] [Abstract][Full Text] [Related]
37. Sphingolipids--the enigmatic lipid class: biochemistry, physiology, and pathophysiology.
Merrill AH; Schmelz EM; Dillehay DL; Spiegel S; Shayman JA; Schroeder JJ; Riley RT; Voss KA; Wang E
Toxicol Appl Pharmacol; 1997 Jan; 142(1):208-25. PubMed ID: 9007051
[TBL] [Abstract][Full Text] [Related]
38. Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis.
Caretti A; Bragonzi A; Facchini M; De Fino I; Riva C; Gasco P; Musicanti C; Casas J; Fabriàs G; Ghidoni R; Signorelli P
Biochim Biophys Acta; 2014 Jan; 1840(1):586-94. PubMed ID: 24141140
[TBL] [Abstract][Full Text] [Related]
39. Biophysics of sphingolipids I. Membrane properties of sphingosine, ceramides and other simple sphingolipids.
Goñi FM; Alonso A
Biochim Biophys Acta; 2006 Dec; 1758(12):1902-21. PubMed ID: 17070498
[TBL] [Abstract][Full Text] [Related]
40. Circulating Sphingolipids and Glucose Homeostasis: An Update.
Ali-Berrada S; Guitton J; Tan-Chen S; Gyulkhandanyan A; Hajduch E; Le Stunff H
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
